Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial

OBJECTIVE: A post hoc analysis to investigate the association between 1-year changes in albuminuria and subsequent risk of cardiovascular and renal events. RESEARCH DESIGN AND METHODS: LEADER was a randomized trial of liraglutide up to 1.8 mg/day versus placebo added to standard care for 3.5–5 years...

Descripción completa

Detalles Bibliográficos
Autores principales: Persson, Frederik, Bain, Stephen C., Mosenzon, Ofri, Heerspink, Hiddo J.L., Mann, Johannes F.E., Pratley, Richard, Raz, Itamar, Idorn, Thomas, Rasmussen, Søren, von Scholten, Bernt Johan, Rossing, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2021
Materias:
Cardiovascular and Metabolic Risk
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985419/
https://www.ncbi.nlm.nih.gov/pubmed/33504496
http://dx.doi.org/10.2337/dc20-1622

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985419/
https://www.ncbi.nlm.nih.gov/pubmed/33504496
http://dx.doi.org/10.2337/dc20-1622

Ejemplares similares